ArticleStroke research and treatment2026
An Intensive and Comprehensive Aphasia Program Versus a Conventional Speech and Language Therapy: A Dose-Controlled, Crossover Experimental Study.
Article in Stroke research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Intensive and Comprehensive Aphasia Program Versus a Conventional Speech and Language Therapy: A Dose-Controlled, Crossover Experimental Study.Stroke research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aphasia, an acquired communication disorder after a stroke, negatively impacts an individual's participation and communicative exchanges in daily life. Speech and language therapy (SLT) serves to either restore or compensate for language capabilities. An intensive and comprehensive aphasia program (ICAP) that emphasizes improving an individual's abilities for daily participation and functional communication through a highly intensive schedule has accumulated substantial evidence supporting its efficacy. This study is aimed at comparing the effects of the mentioned treatment models to firstly progress the investigation of an ICAP in comparison with a conventional model, and secondly, at addressing local service gaps and identify how an ICAP could meet the needs of individuals with aphasia. A nonrandomized, dose-controlled crossover, pre-post design. The ICAP and the conventional SLT (c-SLT) were delivered alternately at a local community-based rehabilitation center in Hong Kong, with a minimum of six-month washout period between programs; treatment allocation was determined by the timing of recruitment. Twelve right-handed adults with chronic aphasia were recruited. Both the treatment models provided 39 hours of treatment, using evidence-based approaches and targeting both word and beyond-word levels. The ICAP phase was delivered over 2.5 weeks at an intensity of 3 hours/day, 5 days/week. Treatment components included individual impairment-based, participation-based, technology-based, and group therapy. The c-SLT phase was delivered at an intensity of 2 hours/week, once weekly, providing individual language-only therapy. Each participant received a total of 78 hours of treatment; no dropouts were recorded. Linguistic performance was assessed using two standardized comprehensive language-functioning tests, an individual naming test and a discourse test. Communication confidence and effectiveness were also evaluated. Overall, the ICAP condition demonstrated better linguistic and quality of life treatment outcomes at the individual and group levels. Feedback on the experiences with the two treatment models was collected through interviews, which provided insights into perceived benefits from the user perspective and insights for future participant recruitment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.